<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00103</drugbank-id>
  <drugbank-id>BTD00075</drugbank-id>
  <drugbank-id>BIOD00075</drugbank-id>
  <name>Agalsidase beta</name>
  <description>Recombinant human alpha-galactosidase A. The mature protein is composed of 2 subunits of 398 residues. Protein is glycosylated and produced by CHO cells</description>
  <cas-number>104138-64-9</cas-number>
  <unii>2HLC17MX9G</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A153</ref-id>
        <pubmed-id>19852524</pubmed-id>
        <citation>Schaefer RM, Tylki-Szymanska A, Hilz MJ: Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs. 2009 Nov 12;69(16):2179-205. doi: 10.2165/11318300-000000000-00000.</citation>
      </article>
      <article>
        <ref-id>A154</ref-id>
        <pubmed-id>20464743</pubmed-id>
        <citation>El Dib RP, Pastores GM: Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev. 2010 May 12;(5):CD006663. doi: 10.1002/14651858.CD006663.pub2.</citation>
      </article>
      <article>
        <ref-id>A155</ref-id>
        <pubmed-id>19725195</pubmed-id>
        <citation>Lim-Melia ER, Kronn DF: Current enzyme replacement therapy for the treatment of lysosomal storage diseases. Pediatr Ann. 2009 Aug;38(8):448-55.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For treatment of Fabry's disease (alpha-galactosidase A deficiency)</indication>
  <pharmacodynamics>Used in the treatment of Fabry disease, an X-linked genetic disorder of glycosphingolipid metabolism. The disease is characterized by a deficiency of the lysosomal enzyme alpha-galactosidase A, which leads to progressive accumulation of glycosphingolipids, predominantly GL-3, in many body tissues. Clinical manifestations of Fabry disease include renal failure, cardiomyopathy, and cerebrovascular accidents. Fabrazyme is intended to provide an exogenous source of alpha-galactosidase A and to limit the accumulation of these glycolipids in the tissues. Studies show unconclusive evidence for the clinical efficacy of either agalasidase alfa or agalasidase beta in preventing morbidity.</pharmacodynamics>
  <mechanism-of-action>Alpha-galactosidase A catalyzes the hydrolysis of globotriaosylceramide (GL-3) and other a-galactyl-terminated neutral glycosphingolipids, such as galabiosylceramide and blood group B substances to ceramide dihexoside and galactose.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life>45-102 min</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance>* 4.1 +/- 1.2 mL/min/kg [adult patients with Fabry disease,0.3 mg/kg, 1 infusion]&#13;
* 4.6 +/- 2.2 mL/min/kg [adult patients with Fabry disease, 0.3 mg/kg, 5 infusions]&#13;
* 2.1 +/- 0.7 mL/min/kg [adult patients with Fabry disease, 1 mg/kg, 1 infusion]&#13;
* 3.2 +/- 2.6 mL/min/kg [adult patients with Fabry disease, 1 mg/kg, 5 infusions]&#13;
* 0.8 +/- 0.3 mL/min/kg [adult patients with Fabry disease, 3 mg/kg, 1 infusion]&#13;
* 0.8 +/- 0.4 mL/min/kg [adult patients with Fabry disease, 3 mg/kg, 5 infusions]&#13;
* 1.8 +/- 0.8 mL/min/kg [Pediatric Patients with Fabry Disease, 1 mg/kg, 1-3 infusions]&#13;
* 4.9 +/- 5.6 mL/min/kg [Pediatric Patients with Fabry Disease, 1 mg/kg, 7 infusions]&#13;
* 2.3 +/- 2.2 mL/min/kg [Pediatric Patients with Fabry Disease, 1 mg/kg, 11 infusions]</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="spanish" coder="">Agalsidasa alfa</synonym>
    <synonym language="spanish" coder="">Agalsidasa beta</synonym>
    <synonym language="english" coder="inn/usan">Agalsidase alfa</synonym>
    <synonym language="english" coder="">Alpha-galactosidase A</synonym>
  </synonyms>
  <products>
    <product>
      <name>Fabrazyme</name>
      <labeller>Genzyme Europe Bv</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000370</ema-product-code>
      <ema-ma-number>EU/1/01/188/001</ema-ma-number>
      <started-marketing-on>2001-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>35 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fabrazyme</name>
      <labeller>Genzyme Europe Bv</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000370</ema-product-code>
      <ema-ma-number>EU/1/01/188/002</ema-ma-number>
      <started-marketing-on>2001-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>35 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fabrazyme</name>
      <labeller>Genzyme Europe Bv</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000370</ema-product-code>
      <ema-ma-number>EU/1/01/188/003</ema-ma-number>
      <started-marketing-on>2001-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>35 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fabrazyme</name>
      <labeller>Genzyme Europe Bv</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000370</ema-product-code>
      <ema-ma-number>EU/1/01/188/004</ema-ma-number>
      <started-marketing-on>2001-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>5 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fabrazyme</name>
      <labeller>Genzyme Europe Bv</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000370</ema-product-code>
      <ema-ma-number>EU/1/01/188/005</ema-ma-number>
      <started-marketing-on>2001-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>5 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fabrazyme</name>
      <labeller>Genzyme Europe Bv</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000370</ema-product-code>
      <ema-ma-number>EU/1/01/188/006</ema-ma-number>
      <started-marketing-on>2001-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>5 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Fabrazyme</name>
      <labeller>Genzyme Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>58468-0041</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>5 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA103979</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fabrazyme</name>
      <labeller>Genzyme Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>58468-0040</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>5 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA103979</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fabrazyme</name>
      <labeller>Sanofi Genzyme, a Division of Sanofi Aventis Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248965</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>5 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fabrazyme</name>
      <labeller>Sanofi Genzyme, a Division of Sanofi Aventis Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248966</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-04-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>35 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Replagal</name>
      <labeller>Shire Human Genetic Therapies Ab</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000369</ema-product-code>
      <ema-ma-number>EU/1/01/189/001</ema-ma-number>
      <started-marketing-on>2001-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution, concentrate</dosage-form>
      <strength>1 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Replagal</name>
      <labeller>Shire Human Genetic Therapies Ab</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000369</ema-product-code>
      <ema-ma-number>EU/1/01/189/002</ema-ma-number>
      <started-marketing-on>2001-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution, concentrate</dosage-form>
      <strength>1 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Replagal</name>
      <labeller>Shire Human Genetic Therapies Ab</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000369</ema-product-code>
      <ema-ma-number>EU/1/01/189/003</ema-ma-number>
      <started-marketing-on>2001-08-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution, concentrate</dosage-form>
      <strength>1 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Replagal</name>
      <labeller>Shire Human Genetic Ther API Es Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02249057</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Fabrazyme</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Fabrazyme</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Fabrazyme</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Fabrazyme</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Fabrazyme</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Fabrazyme</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Replagal</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Replagal</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Replagal</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Fabrazyme</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Fabrazyme</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Fabrazyme</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Fabrazyme</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
    <mixture>
      <name>Replagal</name>
      <ingredients>Agalsidase beta</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Genzyme Inc.</name>
      <url>http://www.genzyme.ca</url>
    </packager>
    <packager>
      <name>Shire Inc.</name>
      <url>http://www.shire.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Fabrazyme 5 mg vial</description>
      <cost currency="USD">771.6</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Fabrazyme 35 mg vial</description>
      <cost currency="USD">5403.6</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Galactosidases</category>
      <mesh-id>D005696</mesh-id>
    </category>
    <category>
      <category>Glycoside Hydrolases</category>
      <mesh-id>D006026</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme</category>
      <mesh-id/>
    </category>
    <category>
      <category>Protein Isoforms</category>
      <mesh-id>D020033</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>35 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>5 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>5 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>35 mg</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>5 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution, concentrate</form>
      <route>Intravenous</route>
      <strength>1 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="A16AB03">
      <level code="A16AB">Enzymes</level>
      <level code="A16A">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A16">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
    <atc-code code="A16AB04">
      <level code="A16AB">Enzymes</level>
      <level code="A16A">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A16">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>44:00.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00103.pdf?1265922797</fda-label>
  <patents>
    <patent>
      <number>2265464</number>
      <country>Canada</country>
      <approved>2007-06-26</approved>
      <expires>2017-09-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Chloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00798</drugbank-id>
      <name>Gentamicin</name>
      <description>The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Gentamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Amiodarone.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00103 sequence
LDNGLARTPTMGWLHWERFMCNLDCQEEPDSCISEKLFMEMAELMVSEGWKDAGYEYLCI
DDCWMAPQRDSEGRLQADPQRFPHGIRQLANYVHSKGLKLGIYADVGNKTCAGFPGSFGY
YDIDAQTFADWGVDLLKFDGCYCDSLENLADGYKHMSLALNRTGRSIVYSCEWPLYMWPF
QKPNYTEIRQYCNHWRNFADIDDSWKSIKSILDWTSFNQERIVDVAGPGGWNDPDMLVIG
NFGLSWNQQVTQMALWAIMAAPLFMSNDLRHISPQAKALLQDKDVIAINQDPLGKQGYQL
RQGDNFEVWERPLSGLAWAVAMINRQEIGGPRSYTIAVASLGKGVACNPACFITQLLPVK
RKLGFYEWTSRLRSHINPTGTVLLQLENTMQMSLKDLL</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.307</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>5.17</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>45351.6</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C2029H3080N544O587S27</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>13296</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>13300</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46508538</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>X14448</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164746527</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P06280</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Agalsidase_beta</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2108888</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/fabrazyme.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/agalsidase-beta.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004830</id>
      <name>Globotriaosylceramide</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A153</ref-id>
            <pubmed-id>19852524</pubmed-id>
            <citation>Schaefer RM, Tylki-Szymanska A, Hilz MJ: Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs. 2009 Nov 12;69(16):2179-205. doi: 10.2165/11318300-000000000-00000.</citation>
          </article>
          <article>
            <ref-id>A154</ref-id>
            <pubmed-id>20464743</pubmed-id>
            <citation>El Dib RP, Pastores GM: Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev. 2010 May 12;(5):CD006663. doi: 10.1002/14651858.CD006663.pub2.</citation>
          </article>
          <article>
            <ref-id>A155</ref-id>
            <pubmed-id>19725195</pubmed-id>
            <citation>Lim-Melia ER, Kronn DF: Current enzyme replacement therapy for the treatment of lysosomal storage diseases. Pediatr Ann. 2009 Aug;38(8):448-55.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>